Vortioxetine, 5, 10, and 20 mg, Relapse Prevention Study in Adults With Major Depressive Disorder (MDD)
Status:
Completed
Trial end date:
2019-04-25
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy of vortioxetine (5, 10, and 20 mg)
versus placebo during the first 28 weeks of the 32-week double-blind treatment period in the
prevention of relapse in participants with MDD who responded to acute treatment with
vortioxetine 10 mg.